Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Systemic Mastocytosis

Interventions

DRUG: Masitinib
DRUG: Placebo
OTHER: Best Supportive Care

Sponsor

AB Science